Journal of Nuclear Cardiology

, Volume 19, Issue 1, pp 92–99 | Cite as

Quantitative I-123 mIBG SPECT in differentiating abnormal and normal mIBG myocardial uptake

  • Ji Chen
  • Russell D. Folks
  • Liudmila Verdes
  • Daya N. Manatunga
  • Arnold F. Jacobson
  • Ernest V. Garcia
Original Article

Abstract

Background

The purpose of this study was to evaluate global quantitation of cardiac uptake on I-123 mIBG SPECT.

Methods

The study included a pilot group of 67 subjects and a validation group of 1,051 subjects. SPECT images were reconstructed by filtered backprojection, ordered subsets expectation maximization, and deconvolution of septal penetration, respectively. SPECT heart-to-mediastinum ratio (H/M) was calculated by comparing the mean counts between heart and mediastinum volumes of interest drawn on transaxial images. Receiver operating characteristic (ROC) analysis was used to assess the capability of each SPECT method to differentiate the heart disease subjects from controls in comparison with that of the planar H/M.

Results

In the validation group, the areas under the ROC curves were not significantly different between the SPECT and planar H/M. Order subsets expectation maximization had significantly larger area under the ROC curve than the other two SPECT methods.

Conclusion

H/M obtained from I-123 mIBG SPECT was equivalent to the planar H/M for differentiating between subjects with normal and abnormal mIBG uptake. Global quantification of cardiac I-123 mIBG SPECT may represent a viable alternative to the planar H/M.

Key Words

Sympathetic nervous system I-123 mIBG SPECT heart failure 

Notes

Disclosure

This study was supported in part by GE Healthcare. Dr Chen, Dr Garcia, and Mr Folks receive royalties from the sale of the Emory Cardiac Toolbox. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict-of-interest practice. Dr Jacobson is an employee of GE Healthcare and owns shares in the General Electric Company.

References

  1. 1.
    Henneman MM, Bengel FM, van der Wall EE, Knuuti J, Bax JJ. Cardiac neuronal imaging: Application in the evaluation of cardiac disease. J Nucl Cardiol 2008;15:442-55.PubMedCrossRefGoogle Scholar
  2. 2.
    Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-23.PubMedGoogle Scholar
  3. 3.
    Fujimoto S, Inoue A, Hisatake S, et al. Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of beta-blockers in patients with dilated cardiomyopathy from the stand-point of long-term prognosis. Eur J Nucl Med Mol Imaging 2004;31:1356-61.PubMedCrossRefGoogle Scholar
  4. 4.
    Nakata T, Wakabayashi T, Kyuma M, et al. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging 2005;32:186-94.PubMedCrossRefGoogle Scholar
  5. 5.
    Anastasiou-Nana MI, Terrovitis JV, Athanasoulis T, et al. Prognostic value of iodine-123-metaiodobenzylguanidine myocardial uptake and heart rate variability in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2005;96:427-31.PubMedCrossRefGoogle Scholar
  6. 6.
    Arimoto T, Takeishi Y, Niizeki T, et al. Cardiac sympathetic denervation and ongoing myocardial damage for prognosis in early stages of heart failure. J Card Fail 2007;13:34-41.PubMedCrossRefGoogle Scholar
  7. 7.
    Kioka H, Yamada T, Mine T, et al. Prediction of sudden death by using cardiac iodine-123 metaiodobenzylguanidine imaging in patients with mid to moderate chronic heart failure. Heart 2007;93:1213-8.PubMedCrossRefGoogle Scholar
  8. 8.
    Kasama S, Toyama T, Kumakura H, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:574-81.PubMedCrossRefGoogle Scholar
  9. 9.
    Kasama S, Toyama T, Hatori T, et al. Evaluation of cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J 2007;28:989-95.PubMedCrossRefGoogle Scholar
  10. 10.
    Kakuchi H, Sasaki T, Ishida Y, Komamura K, Miyatake K. Clinical usefulness of 123I meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart 1999;81:148-52.PubMedGoogle Scholar
  11. 11.
    Gould PA, Kong G, Kalff V, et al. Improvement in cardiac adrenergic function post biventricular pacing for heart failure. Europace 2007;9:751-6.PubMedCrossRefGoogle Scholar
  12. 12.
    Wakabayashi T, Nakata T, Hashimoto A, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001;42:1757-67.PubMedGoogle Scholar
  13. 13.
    Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.PubMedGoogle Scholar
  14. 14.
    Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac metaiodobenzyl-guanidine uptake in patients with moderate chronic heart failure: Relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759-66.PubMedCrossRefGoogle Scholar
  15. 15.
    Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998;5:579-90.PubMedCrossRefGoogle Scholar
  16. 16.
    Kasama S, Toyama T, Kumakura H, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002;43:1279-85.PubMedGoogle Scholar
  17. 17.
    Agostini D, Belin A, Amar MH, et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: A 123I-MIBG scintigraphic study. J Nucl Med 2000;41:845-51.PubMedGoogle Scholar
  18. 18.
    Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF study. J Am Coll Cardiol 2010;55:2212-21.PubMedCrossRefGoogle Scholar
  19. 19.
    Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;55:2767-77.CrossRefGoogle Scholar
  20. 20.
    Chen J, Garcia EV, Galt JR, Folks RD, Carrio I. Optimized acquisition and processing protocols for I-123 cardiac SPECT imaging. J Nucl Cardiol 2006;13:251-60.PubMedGoogle Scholar
  21. 21.
    Chen J, Garcia EV, Galt JR, Folks RD, Carrio I. Improved quantification in I-123 cardiac SPECT imaging with deconvolution of septal penetration. Nucl Med Commun 2006;27:551-8.PubMedCrossRefGoogle Scholar
  22. 22.
    Jacobson AF, Lombard J, Banerjee G, Camici P. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: Design of two prospective multicenter international trials. J Nucl Cardiol 2009;16:113-21.PubMedCrossRefGoogle Scholar
  23. 23.
    Somsen GA, Borm JJ, de Milliano PA, et al. Quantitation of myocardial iodine-123 MIBG uptake in SPET studies: A new approach using the left ventricular cavity and a blood sample as a reference. Eur J Nucl Med 1995;22:1149-54.PubMedCrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2011

Authors and Affiliations

  • Ji Chen
    • 1
  • Russell D. Folks
    • 1
  • Liudmila Verdes
    • 1
  • Daya N. Manatunga
    • 1
  • Arnold F. Jacobson
    • 2
  • Ernest V. Garcia
    • 1
  1. 1.Department of Radiology and Imaging SciencesEmory University School of MedicineAtlantaUSA
  2. 2.GE HealthcarePrincetonUSA

Personalised recommendations